Guardian Pharmacy Services boosts full-year adjusted EBITDA outlook to $123M-$127M after strong Q1 2026 earnings.
Guardian Pharmacy Services reported Q1 2026 revenue of $336.6 million, a 2% year-over-year increase, despite pricing pressures from the Inflation Reduction Act. Gross profit rose 19% to $76 million, while adjusted EBITDA jumped 27% to $29.8 million, driven by favorable payer dynamics and a one-time manufacturer inventory credit.
The company maintained its full-year revenue guidance of $1.4 billion-$1.42 billion but raised its adjusted EBITDA outlook to $123 million-$127 million. Management noted the IRA transition aligned with expectations and emphasized continued acquisition growth.
Executives described the quarter as a successful navigation of the IRA’s new framework, highlighting double-digit growth in residents and script volumes.